BABA vs CCK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.
CCK presents a conflicted profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $101.13 trades well above the Graham Number ($61.95) and Intrinsic Value ($44.66). While the company maintains a strong ROE of 26.33% and a very attractive PEG ratio of 0.64, these are offset by a severe YoY earnings contraction of -56.40%. Bearish insider activity from the CEO and COO, combined with a low quick ratio, suggests caution despite bullish analyst targets.
Compare Another Pair
Related Comparisons
BABA vs CCK: Head-to-Head Comparison
This page compares Alibaba Group Holding Limited (BABA) and Crown Holdings, Inc. (CCK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.